[1]Marelli L, Stigliano R, Triantos C, et al.Transarterial therapyfor hepatocellular carcinoma:which technique is moreeffective?A systematic review of cohort and randomizedstudies[J].Cardiovasc Intervent Radiol, 2007, 30 (1) :6-25.
|
[2]中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001, 9 (6) :324.
|
[3]Kim JH, Kim JIH, Choi JH, et al.Value of the model for end-stageliver disease for predicting survival in hepatocellular carcinomapatients treated with transarterial chemoembolization[J].Scand JGastroenterol, 2009, 44 (3) :346-357.
|
[4]Cho YK, Chung JW, Kim JK, et al.Comparison of 7 staging systemsfor patients with hepatocellular carcinoma undergoing transarterialchemoembolization[J].Cancer, 2008, 112 (2) :352-361.
|
[5]Georgiades CS, Liapi E, Frangakis C, et al.Prognostic accuracy of12 liver staging systems in patients with unresectable hepatocellularcarcinoma treated with transarterial chemoembolization[J].J VascInterv Radiol, 2006, 17 (10) :1619-1624.
|
[6]李怀波, 张振清, 戴函碧, 等.肝癌患者介入治疗后长期生存的综合分析[J].中国医学影像技术, 2009, 25 (12) :2286-2289.
|
[7]张晓勇.肝动脉化疗栓塞治疗原发性肝癌的疗效及预后多因素分析[J].实用预防医学, 2009, 16 (3) :872-873.
|
[8]罗懿忠, 区金锐.TNM分期评价肝癌术后TACE及预后的价值[J].广东医学, 2009, 30 (11) :1701-1703.
|
[9]Chen CH, Hu FC, Huang GT, et al.Applicability of stagingsystems for patients with hepatocellular carcinoma isdependent on treatment method-Analysis of 2010 Taiwanesepatients[J].Eur J Cancer, 2009, 45 (1) :1630-1639.
|
[10]Bruix J, Sherman M, Llovet JM, et al.Clinical managementof hepatocellular carcinoma.Conclusions of the Barcelona-2000 EASL Conference[J].J Hepatol, 2001, 35 (3) :421-430.
|
[11]Cillo U, Bassanello M, Vitale A, et al.The critical issue ofhepatocellular carcinoma prognostic classification:which isthe best tool available?[J].J Hepatol, 2004, 40 (1) :124-131.
|
[12]Llovet JM, Bru C, Bruix J.Prognosis of hepatocelluarcarcinoma:BCLC staging classification[J].Semin LiverDis, 1999, 19 (3) :329-337
|
[13]Llovet JM, Burroughs A, Bruix J.Hepatocellular carcinoma[J].Lancet, 2003, 362 (9399) :1907-1917.
|